About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., the company develops next-generation antibody complement therapeutics — led by DNTH103, a monoclonal antibody targeting the active form of complement C1s — aimed at delivering transformative medicines for people living with severe autoimmune and inflammatory diseases. The company is publicly traded on Nasdaq under the ticker DNTH.
Company details
Funding
Total raised
$100M
Last stage
Public
Investors
Founders
Tomas Kiselak
Co-founder of Dianthus Therapeutics and Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co-founded. Previously a managing director at RA Capital Management.
Jonathan Violin
Dr. Violin co-founded Dianthus in July 2019 and has served on the Board of Directors since. He previously co-founded Viridian Therapeutics and Trevena Inc., and served as founding CEO of Quellis Biosciences.
LinkedInMarino Garcia
Seasoned biotech executive appointed as CEO at Dianthus Therapeutics' launch; leads the company's clinical development of next-generation complement therapeutics for autoimmune diseases.
Lonnie Moulder
Co-founder of Dianthus Therapeutics and Founder & Managing Member of Tellus BioVentures; transitioned from the Board of Directors in 2025.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.